The family of apoptosis-stimulating proteins of p53 is dysregulated in colorectal cancer patients

Yin,Libin; Lin,Yuyang; Wang,Xu; Su,Yanzhuo; Hu,Han; Li,Chao; Wang,Lei; Jiang,Yanfang

doi:10.3892/ol.2018.8151

The family of apoptosis-stimulating proteins of p53 is dysregulated in colorectal cancer patients

Authors:
- Libin Yin
- Yuyang Lin
- Xu Wang
- Yanzhuo Su
- Han Hu
- Chao Li
- Lei Wang
- Yanfang Jiang
View Affiliations

Affiliations: Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Gastrointestinal Colorectal and Anal Surgery, China Japan Union Hospital of Jilin University, Changchun, Jilin 130000, P.R. China, Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: March 1, 2018 https://doi.org/10.3892/ol.2018.8151
Pages: 6409-6417
Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The apoptosis-stimulating protein of p53 (ASPP) family is a newly identified family protein including ASPP1, ASPP2 and inhibitor of ASPP (iASPP), by which the tumor protein 53 (TP53)‑mediated apoptotic process is selectively regulated. Downregulation of ASPP1/ASPP2 and upregulation of iASPP were revealed to be associated with a poor prognosis and metastasis in several types of cancer. However, to the best of our knowledge, the expression of ASPP in colorectal cancer (CRC) has not previously been investigated. The present study analyzed ASPP expression in human CRC tissues with multiple clinical and pathological profiles. A total of 41 patients diagnosed with CRC were enrolled in the present study. The expression of ASPP was detected by immunohistochemistry, immunofluorescence and reverse transcription-quantitative polymerase chain reaction. In addition, the variation in ASPP expression was examined in a number of pathological groups. The associations among ASPP expression, and the expression of TP53, plasma carcinoembryonic antigen (CEA) levels and α‑fetoprotein (AFP) levels were also investigated. ASPP1 and ASPP2 expression was significantly reduced, while iASPP expression was elevated in CRC samples compared with expression in adjacent non‑cancerous tissues. Downregulation of ASPP1 was detected in the TP53‑positive group compared with the TP53‑negative group. The increase in iASPP expression was correlated with the grade of malignancy, but not with regional lymph node status or metastases. The expression of ASPP2 was negatively correlated with plasma CEA levels. The results of the present study, not only enrich CRC epidemic and pathological data, but also provide valuable indices for CRC clinical treatment and prognosis.

View Figures

View References

1	Haggar FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
2	Shah TA: Colonic cancer; presentation and management in a surgical unit at allied hospital faisalabad. Prof Med J. 23:251–256. 2016.
3	Croce CM: Oncogenes and cancer. N Engl J Med. 358:502–511. 2008. View Article : Google Scholar : PubMed/NCBI
4	Trigiante G and Lu X: ASPP [corrected] and cancer. Nat Rev Cancer. 6:217–226. 2006. View Article : Google Scholar : PubMed/NCBI
5	Chao C, Saito S, Kang J, Anderson CW, Appella E and Xu Y: p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J. 19:4967–4975. 2000. View Article : Google Scholar : PubMed/NCBI
6	Vousden KH and Lu X: Live or let die: The cell's response to p53. Nat Rev Cancer. 2:594–604. 2002. View Article : Google Scholar : PubMed/NCBI
7	Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science. 253:49–53. 1991. View Article : Google Scholar : PubMed/NCBI
8	Starks AM, Martin DN, Dorsey TH, Boersma BJ, Wallace TA and Ambs S: Household income is associated with the p53 mutation frequency in human breast tumors. PLoS One. 8:e573612013. View Article : Google Scholar : PubMed/NCBI
9	Soussi T, Kato S, Levy PP and Ishioka C: Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat. 25:6–17. 2005. View Article : Google Scholar : PubMed/NCBI
10	Vazquez A, Bond EE, Levine AJ and Bond GL: The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 7:979–987. 2008. View Article : Google Scholar : PubMed/NCBI
11	Shi Y, Han Y, Xie F, Wang A, Feng X, Li N, Guo H and Chen D: ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy. J Cell Mol Med. 19:535–543. 2015. View Article : Google Scholar : PubMed/NCBI
12	Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES and Cheung AN: Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation. Carcinogenesis. 34:2170–2177. 2013. View Article : Google Scholar : PubMed/NCBI
13	Schittenhelm MM, Illing B, Ahmut F, Rasp KH, Blumenstock G, Döhner K, Lopez CD and Kampa-Schittenhelm KM: Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. PLoS One. 8:e801932013. View Article : Google Scholar : PubMed/NCBI
14	Song B, Bian Q, Zhang YJ, Shao CH, Li G, Liu AA, Jing W, Liu R, Zhou YQ, Jin G and Hu XG: Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation. Mol Cancer. 14:1772015. View Article : Google Scholar : PubMed/NCBI
15	Meng WD, Chu RX, Wang BZ, Wang LP, Ma LL and Wang LX: Infection à Helicobacter pylori et les expressions de l'apoptose liée à p53, PAES et PPEEE dans le cancer gastrique et des lésions précancéreuses. Pathol Biol. 61:199–202. 2013. View Article : Google Scholar : PubMed/NCBI
16	Li S, Shi G, Yuan H, Zhou T, Zhang Q, Zhu H and Wang X: Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP. Oncol Rep. 28:133–140. 2012.PubMed/NCBI
17	Mori T, Okamoto H, Takahashi N, Ueda R and Okamoto T: Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett. 465:124–128. 2000. View Article : Google Scholar : PubMed/NCBI
18	Lossos IS, Natkunam Y, Levy R and Lopez CD: Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: Correlation with clinical outcome. Leuk Lymphoma. 43:2309–2317. 2002. View Article : Google Scholar : PubMed/NCBI
19	Lu B, Guo H, Zhao J, Wang C, Wu G, Pang M, Tong X, Bu F, Liang A, Hou S, et al: Increased expression of iASPP, regulated by hepatitis B virus X protein-mediated NF-κB activation, in hepatocellular carcinoma. Gastroenterology. 139:2183–2194.e5. 2010. View Article : Google Scholar : PubMed/NCBI
20	Kim KH, Yang SS, Yoon YS, Lim SB, Yu CS and Kim JC: Validation of the seventh edition of the American joint committee on cancer tumor-node-metastasis (AJCC TNM) staging in patients with stage II and stage III colorectal carcinoma: Analysis of 2511 cases from a medical centre in Korea. Colorectal Dis. 13:e220–e226. 2011. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR Jr and Elkahloun AG: In vivo gene expression profile analysis of human breast cancer progression. Cancer Res. 59:5656–5661. 1999.PubMed/NCBI
23	Anzai H, Kazama S, Kiyomatsu T, Nishikawa T, Tanaka T, Tanaka J, Hata K, Kawai K, Yamaguchi H, Nozawa H, et al: Alpha-fetoprotein-producing early rectal carcinoma: A rare case report and review. World J Surg Oncol. 13:1802015. View Article : Google Scholar : PubMed/NCBI
24	Michl M, Stintzing S, von Weikersthal Fischer L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, et al: CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Ann Oncol. 27:1565–1572. 2016. View Article : Google Scholar : PubMed/NCBI
25	Huo YR, Glenn D, Liauw W, Power M, Zhao J and Morris DL: Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases. Eur Radiol. 27:128–137. 2017. View Article : Google Scholar : PubMed/NCBI
26	Kong F, Shi X, Li H, Li P, Yu J, Li X, Chen J, Sun Y and Jia Y: Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection. Am J Cancer Res. 5:12172015.PubMed/NCBI
27	Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG and Shak S: Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 11:8623–8631. 2005. View Article : Google Scholar : PubMed/NCBI
28	Vives V, Su J, Zhong S, Ratnayaka I, Slee E, Goldin R and Lu X: ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev. 20:1262–1267. 2006. View Article : Google Scholar : PubMed/NCBI
29	Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T and Lu X: ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 8:781–794. 2001. View Article : Google Scholar : PubMed/NCBI
30	Liu ZJ, Lu X, Zhang Y, Zhong S, Gu SZ, Zhang XB, Yang X and Xin HM: Downregulated mRNA expression of ASPP and the hypermethylation of the 5′-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett. 579:1587–1590. 2005. View Article : Google Scholar : PubMed/NCBI
31	Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, Takahashi M, Fong KM, Shimokata K and Sekido Y: p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer. 100:1673–1682. 2004. View Article : Google Scholar : PubMed/NCBI
32	Sullivan A and Lu X: ASPP: A new family of oncogenes and tumour suppressor genes. Br J Cancer. 96:196–200. 2007. View Article : Google Scholar : PubMed/NCBI
33	Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, et al: iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet. 33:162–167. 2003. View Article : Google Scholar : PubMed/NCBI
34	Zhang X, Wang M, Zhou C, Chen S and Wang J: The expression of iASPP in acute leukemias. Leuk Res. 29:179–183. 2005. View Article : Google Scholar : PubMed/NCBI
35	Liu ZJ, Zhang Y, Zhang XB and Yang X: Abnormal mRNA expression of ASPP members in leukemia cell lines. Leukemia. 18:8802004. View Article : Google Scholar : PubMed/NCBI
36	Lettre G, Kritikou EA, Jaeggi M, Calixto A, Fraser AG, Kamath RS, Ahringer J and Hengartner MO: Genome-wide RNAi identifies p53-dependent and -independent regulators of germ cell apoptosis in C. elegans. Cell Death Differ. 11:1198–1203. 2004. View Article : Google Scholar : PubMed/NCBI
37	Gorina S and Pavletich NP: Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science. 274:1001–1005. 1996. View Article : Google Scholar : PubMed/NCBI
38	Denoix PF: Enquete permanent dans les centres anticancereaux. Bull Inst Natl Hyg. 1:701946.
39	Thomas SN, Zhu F, Schnaar RL, Alves CS and Konstantopoulos K: Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem. 283:15647–15655. 2008. View Article : Google Scholar : PubMed/NCBI
40	Konstantopoulos K and Thomas SN: Cancer cells in transit: The vascular interactions of tumor cells. Annu Rev Biomed Eng. 11:177–202. 2009. View Article : Google Scholar : PubMed/NCBI
41	Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES and Cheung AN: Downregulation of ASPP1 in gestational trophpblastic disease: Correlation with hypermethylation, apoptopic activity and clinical outcome. Mod Pathol. 24:522–532. 2011. View Article : Google Scholar : PubMed/NCBI
42	Thomas SN, Tong Z, Stebe KJ and Konstantopoulos K: Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics. Biorheology. 46:207–225. 2009.PubMed/NCBI
43	O'Conor GT, Tatarinov YS, Abelev GI and Uriel J: A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer. 25:1091–1098. 1970. View Article : Google Scholar : PubMed/NCBI
44	Smith CJ, Ajdukiewicz A and Kelleher PC: Concanavalin-A-affinity molecular heterogeneity of human hepatoma AFP and cord-serum AFP. Ann N Y Acad Sci. 417:69–74. 1983. View Article : Google Scholar : PubMed/NCBI
45	Norgaard-Pedersen R, Albrechtsen R and Teilum G: Serum alpha-foetoprotein as a marker for endodermal sinus tumour (yolk sac tumour) or a vitelline component of ‘teratocarcinoma’. Acta Pathol Microbiol Scand A. 83:573–589. 1975.PubMed/NCBI